NASD · Healthcare · Medical Devices · USA
MaxCyte Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.
MaxCyte Inc develops and commercializes Flow Electroporation technology, a platform for engineering cells used in cell and gene therapies. The company provides the ExPERT family of instruments, disposables, and consumables that enable delivery of molecules into various cell types across research and manufacturing scales. Its customers include biopharmaceutical companies, biotechnology firms, and academic institutions developing next-generation cell-based therapeutics.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the MaxCyte Inc stock.
Overvalued: intrinsic value $0.85 per share, market price $1.17, margin of safety -38.3% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $0.85; the price of $1.17 is 38% above that value.
1 more funds hold it; the full list is part of the paid plan.
All 140 Medical Devices stocks
27 more in this industry show a wider margin of safety.
MXCT is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.85; the price of $1.17 is 38% above that value.
$0.85 per share (as of the 2026-11-17 close), against a market price of $1.17. That is a margin of safety of -38.3%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.